Navigation Links
Max Neeman International to Open Phase I/IIa Unit
Date:9/23/2009

RESEARCH TRIANGLE PARK, N.C., Sept. 23 /PRNewswire/ -- Max Neeman International, a leading Indian CRO, announced a partnership with Max Healthcare to open a Phase I/IIa clinical trial unit at Max Super Speciality Hospital, New Delhi, India. This proof of concept unit will allow Pharmaceutical, Biotech & Device companies the option to complete a critical part of the development process across multiple therapeutic areas quickly and with the highest quality.

The new Phase I/IIa unit will evaluate compounds/devices developed both in India and in other countries. This unit will provide end-to-end services and will have approximately 24 beds, with plans to expand this number to 50 to meet predicted growth in demand.

This new Phase I/IIa unit will draw on the experience of its partners and the expertise of local clinicians and scientists to deliver studies in accordance with global standards and within the regulatory framework in India.

Our partner Max Healthcare, with over 800 beds and 8 hospitals in Delhi is one of the leading hospital chains in India and has an outstanding reputation and track record for quality health care provision in India.

About Max Healthcare

With over 800 beds and 8 hospitals in Delhi, and with over 1500 physicians and 3000 support staff - Max Healthcare is one of a leading chain of hospitals in India. Its state of the art infrastructure, over 225 ICU beds and most advanced technologies makes it one of the best hospitals in India. http://www.maxhealthcare.in

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India providing a full range of clinical services to global Pharmaceutical, Biotech and Device companies. Operational since 2001, it is an ISO 9001:2000 certified CRO for Monitoring, Site Management and Data Management Services. Presently, it is active in 22 cities with 5 regional offices. Please contact Donald Swankie, Vice President of Business Development for more information (donald.swankie@neeman-medical.com/ +1.919.424.3345). http://www.neeman-medical.com


'/>"/>
SOURCE Max Neeman International
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
3. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
4. Arrow International Files and Mails Definitive Proxy Materials
5. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
6. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
7. Viragen International to Reverse Split Its Common Stock
8. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
9. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
10. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
11. Biosafety and Biosecurity International Conference 2007 to be held in Abu Dhabi from November 12 to 14
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):